艾迪药业(688488.SH)：拟以1.3亿元收购南大药业22.2324%股权

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), plans to acquire a total of 22.2324% equity in its subsidiary, Nanda Pharmaceutical, from minority shareholders for a price of 130.05954 million yuan, enhancing its control and aligning with its strategic goals [1] Group 1: Acquisition Details - The company intends to purchase 19.6337% of Nanda Pharmaceutical's equity from Huatai Guoxin, 0.0987% from Daoxing Venture Capital, and 2.5000% from Yao Fandi [1] - The acquisition will be financed through the company's own or raised funds [1] Group 2: Strategic Implications - This acquisition will strengthen the company's control over Nanda Pharmaceutical, ensuring the steady implementation of its "human-derived protein raw materials - formulation integration" strategy [1] - Increasing the stake in Nanda Pharmaceutical is expected to enhance the company's performance, as the subsidiary has shown stable growth in revenue and profit in recent years [1]